Rechallenge with lamotrigine after a rash: A prospective case series and review of the literature

Psychiatry (Edgemont)

Volumn 7, Issue 5, 2010, Pages 27-32

  Aiken, Chris B ^a   Orr, Carolyn ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Mood Treatment Center   (United States)

Author keywords

Anticonvulsants administration and dosage; Anticonvulsants adverse effects; Bipolar disorder; Drug eruptions; Exanthema chemically induced; Exanthema prevention and control; Lamotrigine; Triazines administration and dosage; Triazines adverse effects

Indexed keywords

LAMOTRIGINE;

ARTICLE; BIPOLAR DEPRESSION; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG RECHALLENGE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INFLAMMATION; LOW DRUG DOSE; OPEN STUDY; PROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 77956125906     PISSN: 15505952     EISSN: 15555194     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hirsch LJ, Weintraub DB, Buchsbaum R, et al. Predictors of lamotrigine-associated rash. Epilepsia. 2006;47:318-322
2. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother. 1999;33:1037-1042
3. Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology. 2007;68:1701-1709.
4. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia. 2007;48:1360-1365.
5. GlaxoSmithKline. Lamictal® prescribing information. http://us.gsk.com/products/assets/us_lamictal.pdf. Accessed on May 1, 2008.
6. Bowden CL, Asnis GM, Ginsberg LD, et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf. 2004;27:173-184.
7. Mockenhaupt M, Messenheimer J, Tennis P, et al. Risk of Stevens- Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64:1134-1138.
8. Messenheimer JA. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis among new users of antiepileptic drugs: S41.004: 4:45 PM Neurology. 2004;62(suppl S5):A352
9. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002;63:1012-1019.
10. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261-269.
11. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530-537.
12. Judd LL, Schettler PJ, Akiskal HS, et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol. 2003;6:127-137.
13. Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure. 2007;16:296-304.
14. Gualtieri CT, Johnson LG. Comparative neurocognitive effects of 5 psychotropic anticonvulsants and lithium. MedGenMed. 2006;8:46.
15. Khan A, Ginsberg LD, Asnis GM, et al. Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. J Clin Psychiatry. 2004;65:1483-1490.
16. Kaye NS, Graham J, Roberts J, et al. Effect of open-label lamotrigine as monotherapy and adjunctive therapy on the self-assessed cognitive function scores of patients with bipolar I disorder. J Clin Psychopharmacol. 2007;27:387-391.
17. Ketter TA, Wang PW, Chandler RA, et al. Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. J Clin Psychiatry. 2005;66:642-645.
18. Ketter TA, Greist JH, Graham JA, et al. The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial. J Clin Psychiatry. 2006;67:400-406.
19. Shear NH, Knowles SR, Sullivan JR, et al. Cutaneous reactions to drugs. In: Freedburg IM, Eisen AZ, Wolff K, et al (eds). Fitzpatrick's Dermatology in General Medicine, Sixth Edition. New York, NY: McGraw-Hill; 2003:1330-1337.
20. Guy W. Clinical Global Impressions. In: Guy W. (ed). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Dept of Health, Education and Welfare; 1976.
21. Gelisse P, Crespel A. [Reintroduction of treatment with lamotrigine in combination with valproate after an initial allergic skin reaction] Rev Neurol. 2006;162:1122-1124.
22. P-Codrea Tigaran S, Sidenius P, Dam M. Lamotrigine-induced rashworth a rechallenge. Acta Neurol Scand. 2005;111:191-194.
23. Manfredi G, Pacchiarotti I, Kotzalidis GD, et al. Successful rechallenge with slowly titrated lamotrigine after rash. Bipolar Disord. 2004;6:338-339.
24. Besag FM, Ng GY, Pool F. Successful re-introduction of lamotrigine after initial rash. Seizure. 2000;9:282-286.
25. Buzan RD, Dubovsky SL. Recurrence of lamotrigineassociated rash with rechallenge. J Clin Psychiatry.1998;59:87.
26. Tavernor SJ, Wong IC, Newton R, et al. Rechallenge with lamotrigine after initial rash. Seizure. 1995;4:67-71.
27. Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia. 1994;35:359-367.
28. Li LM, Russo M, O'Donoghue MF, et al. Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arq Neuropsiquiatr. 1996;54:47-49.
29. Singh J. Zarate CA Jr. Krystal AD. Case report: successful riluzole augmentation therapy in treatmentresistant bipolar depression following the development of rash with lamotrigine. Psychopharmacology. 2004;173:227-228.
30. Huang CW, Tsai JJ, Lai ML. Lamotrigine-related skin rashes in adults. Kaohsiung J Med Sci. 2002;18:566-572.
31. Goodwin F, Jamison K. Manic Depressive Illness, Second Edition. New York, NY: Oxford University Press; 2007.
32. Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009;60:147-156.